Trial · NCT02259114
Results by group70
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 70
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | MK-8628 Continuous Dosing Regimen 80 mg/Day | 4 | Participants | ||
| Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | MK-8628 Continuous Dosing Regimen 100 mg/Day | 2 | Participants | ||
| Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | MK-8628 Days 1-7 Dosing Regimen 100 mg/Day | 0 | Participants | ||
| Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | MK-8628 Days 1-7 Dosing Regimen 120 mg/Day | 0 | Participants | ||
| Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | MK-8628 Days 1-7 Dosing Regimen 160 mg/Day | 0 | Participants | ||
| Number of Participants Who Experienced at Least One Adverse Event (AE) | MK-8628 Continuous Dosing Regimen 80 mg/Day | 20 | Participants | ||
| Number of Participants Who Experienced at Least One Adverse Event (AE) | MK-8628 Continuous Dosing Regimen 100 mg/Day | 4 | Participants | ||
| Number of Participants Who Experienced at Least One Adverse Event (AE) | MK-8628 Days 1-7 Dosing Regimen 100 mg/Day | 13 | Participants | ||
| Number of Participants Who Experienced at Least One Adverse Event (AE) | MK-8628 Days 1-7 Dosing Regimen 120 mg/Day | 3 | Participants | ||
| Number of Participants Who Experienced at Least One Adverse Event (AE) | MK-8628 Days 1-7 Dosing Regimen 160 mg/Day | 6 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | MK-8628 Continuous Dosing Regimen 80 mg/Day | 5 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | MK-8628 Continuous Dosing Regimen 100 mg/Day | 3 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | MK-8628 Days 1-7 Dosing Regimen 100 mg/Day | 2 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | MK-8628 Days 1-7 Dosing Regimen 120 mg/Day | 0 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | MK-8628 Days 1-7 Dosing Regimen 160 mg/Day | 1 | Participants | ||
Best Overall Response as Assessed in Solid Tumors by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or in Castration-resistant Prostate Cancer (CRPC) by Prostate Cancer Clinical Trials Working Group (PCWG2) Response Criteria | MK-8628 Continuous Dosing Regimen 80 mg/Day | Complete Response | 0 | Participants | |
Best Overall Response as Assessed in Solid Tumors by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or in Castration-resistant Prostate Cancer (CRPC) by Prostate Cancer Clinical Trials Working Group (PCWG2) Response Criteria | MK-8628 Continuous Dosing Regimen 100 mg/Day | Complete Response | 0 | Participants | |
Best Overall Response as Assessed in Solid Tumors by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or in Castration-resistant Prostate Cancer (CRPC) by Prostate Cancer Clinical Trials Working Group (PCWG2) Response Criteria | MK-8628 Days 1-7 Dosing Regimen 100 mg/Day | Complete Response | 0 | Participants | |
Best Overall Response as Assessed in Solid Tumors by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or in Castration-resistant Prostate Cancer (CRPC) by Prostate Cancer Clinical Trials Working Group (PCWG2) Response Criteria | MK-8628 Days 1-7 Dosing Regimen 120 mg/Day | Complete Response | 0 | Participants | |
Best Overall Response as Assessed in Solid Tumors by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or in Castration-resistant Prostate Cancer (CRPC) by Prostate Cancer Clinical Trials Working Group (PCWG2) Response Criteria | MK-8628 Days 1-7 Dosing Regimen 160 mg/Day | Complete Response | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02259114/results